Moghaddam et al. have utilized a K-ras induced lung cancer mouse model to demonstrate that K-ras activation drives a pro-tumor immune suppressive microenvironment with increased type 2 and reduced type 1 inflammatory signatures via IL-6 signaling. The gene discussed is IL6; the disease is lung carcinoma.